Tian Zhang, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Grants

Publications

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID
32392161
Full Text

Zhang, Tian, Joyce K. Hwang, Daniel J. George, and Sumanta K. Pal. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.” Cancer Treat Res Commun 24 (June 12, 2020): 100183. https://doi.org/10.1016/j.ctarc.2020.100183.

PMID
32563923
Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID
32253061
Full Text

Brady-Nicholls, Renee, John D. Nagy, Travis A. Gerke, Tian Zhang, Andrew Z. Wang, Jingsong Zhang, Robert A. Gatenby, and Heiko Enderling. “Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.” Nat Commun 11, no. 1 (April 9, 2020): 1750. https://doi.org/10.1038/s41467-020-15424-4.

PMID
32273504
Full Text

Labriola, Matthew Kyle, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.

PMID
32221016
Full Text

Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Hannah Berg, et al. “Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Agarwal, Anika, Jennifer Modliszewski, Lauren Davey, Marco Reyes-Martinez, Daniella Runyambo, David Corcoran, Holly Dressman, et al. “Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Desai, Kunal, Landon Carter Brown, Wei Wei, Kimberly D. Allman, Allison Martin, Laura S. Wood, Shilpa Gupta, et al. “Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Brown, Landon Carter, Kunal Desai, Chester Kao, Emily Noelle Kinsey, Patrick Healy, Julie Kephart, Michael Roger Harrison, et al. “A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.

Scholars@Duke

Pages